On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novavax expects post-marketing COVID study to cost up to $90M; New Novo CEO set to reallocate struggling drugmaker’s resources; WSJ editorial board argues against Trump’s MFN proposal.

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...